Kornimate/medical-research-clean huggingface dataset:
changes in pelvic health, sexual function, and quality of life in women with pelvic cancer undergoing radiation therapy

Conditions: Anal Carcinoma; Cervical Carcinoma; Endometrial Carcinoma; Malignant Pelvic Neoplasm; Rectal Carcinoma; Vaginal Carcinoma; Vulvar Carcinoma

Summary: this study investigates changes in physical measures of pelvic health and patient-reported outcomes of sexual function, intimate relationship, and quality of life over time in women undergoing radiation therapy for pelvic cancer. evaluating vaginal changes prior to and after a course of radiation and collecting patient reported outcomes of sexual function, partner communication, and intimacy may help researchers may help researchers better understand physical changes and symptoms over time.

primary objectives: i. to evaluate changes in objective physical exam findings from baseline to the end of radiation and through two years follow-up for women with pelvic cancer. ii. to examine changes in sexual, relational and quality of life outcomes from baseline to the end of radiation and through one year follow-up for women with pelvic cancer using the patient reported outcome measures. iii. to compare physical exam and patient-reported outcome trajectories over time. outline: patients undergo standard of care pelvic exam at baseline and 1, 3, 6, 12, and 24 month follow ups. patients also complete patient reported outcome measures at baseline and 1, 3, 6, 12, 18, and 12 month follow ups.

Eligibility criteria:
inclusion criteria: * any patient with anal, rectal, cervical, endometrial, vaginal, or vulvar cancer receiving external beam radiation alone, brachytherapy alone, or both external beam radiation and brachytherapy * concurrent or prior chemotherapy is allowed, including those participating in ohio state university (osu)-16166 * any prior gynecologic surgery is permitted * rectal surgery, including lower anterior resection and abdominoperineal resection, is permitted exclusion criteria: * patients with scleroderma, mixed connective tissue disorder, and lupus will be excluded * patients who have received prior pelvic radiation
relaxation and heart rate variability

Conditions: Cancer

Summary: primary: * to characterize the physiologic changes of the autonomic nervous system, demonstrated by heart rate variability (hrv) high frequency (hf) spectral analysis, before and after a 15 minute, one-time, guided relaxation program for cancer patients. secondary: * to assess whether change of hrv correlates with subjective feeling for anxiety, based on visual analog scale scores.

rhythm changes in your heart rate are part of the "autonomic" nervous system. this is the part of your nervous system that controls the body functions that you do not have to think about. researchers want to find out if a "guided relaxation" session will make your heart rate more variable, with more rhythm changes. if you are found to be eligible to take part in this study, you will first answer a brief questionnaire that will measure several symptoms, such as pain and anxiety (worry). this questionnaire will take less than 5 minutes. you will also be asked questions about your alcohol and smoking history, and if you have ever used relaxation or meditation techniques in the past. this will also take less than 5 minutes. you will then be asked to lay on your back, on a hospital bed or exam table. electrodes will be placed along your chest, the same way they are placed for an electrocardiogram (ecg--a test to measure the electrical activity of the heart). you will be asked to rest for 15 minutes, and then your heart rhythm will be recorded for 5 minutes. after this first recording, you will begin the relaxation program by listening to an audio recording for about 15 minutes, using headphones. after the relaxation program has ended, your heart rhythm will be recorded for another 5-minute period while you are resting. you will then be asked to complete the same questionnaire as before. the entire procedure will take about 45-60 minutes. after this second questionnaire, your participation on this study will be over. this is an investigational study. up to 20 people will take part in this study. all will be enrolled at m. d. anderson.

Eligibility criteria:
inclusion criteria: 1. written informed consent 2. normal cognition (per treating physician's assessment) exclusion criteria: 1. dementia 2. psychosis 3. delirium 4. not fluent in english 5. cardiac dysrhythmia 6. inability to lay supine 7. pacemaker

Keywords: advanced cancer cancer patients relaxation therapy relaxation and heart rate variability guided relaxation hrv stress, anxiety, and panic disorder
examining the effects of float-rest for recovery in individuals with chronic lower back pain

Conditions: Pain, Chronic

Summary: researchers at the west virginia university rockefeller neuroscience institute are looking for volunteers to participate in a research study to evaluate what effects float-rest (restricted environmental stimulation technique) has on the stress response caused by chronic lower back pain.

chronic lower back pain has a profound impact on a patient's life and body. these patients face a litany of internal and external stressors. these stressors cause a detrimental sustained activation of the endogenous stress response, which is mediated by the autonomic nervous system. our central hypothesis is that this high stress load exacerbates the symptoms of chronic pain by causing changes in how the brain processes pain signals from the periphery. if researchers can better understand how stress plays a role in the mitigation of pain, then there may be improvements in patient's quality of life. restricted environmental stimulation therapy (rest) flotation has been identified as a possible alternative treatment to pharmacological intervention for several conditions like generalized anxiety disorder by helping to reduce stress. however, there have yet to be any investigation into what affects that rest flotation has in chronic lower back pain.

Eligibility criteria:
inclusion criteria: * able and willing to give informed consent * right-hand dominant * naïve to mindfulness interventions (i.e. guided meditation, guided yoga, previous rest flotation) * have chronic lower back pain (at least 12 weeks since onset) * ability to enter/exit rest flotation tank unassisted * stable prescription medication (no changes in dose, start/stop within 30 days of the beginning of the study) exclusion criteria: * mri incompatibility: the participant cannot have any non-mri compatible metallic (magnetic) material in, on, or attached to their body. * current fear of small spaces or water * current balance problems or motion sickness * body width greater than 60cm * current contagious skin condition

Keywords: sensory deprivation tank fmri
long-term review of a cohort of arthroscopic bankart interventions

Conditions: Recurrent Anterior Shoulder Instability

Summary: recurrent instability is the most common chronic shoulder pathology of the young and athletic patient. it is a source of functional, sporting and professional disability, and a permanent apprehension to the use of the affected shoulder. surgical treatment has been proposed for a long time by the reintegration of the labrum (intervention of bankart) then by the making of an osteo-muscular stop (intervention of latarjet). like in many domains, surgical techniques have evaluated towards the search for endoscopic alternatives to open surgery, more deleterious. bankart's intervention has been performed arthroscopically since the 1980s and remains the majority intervention in the united states. however, its success rate never reached that of open techniques, bankart and latarjet. surgeons therefore sought the predictors of these failures in order to define the limits of the indications for arthroscopic bankart intervention. the determination and use of the preoperative instability score (instability severity index score : isis) described by balg and boileau is one of the ways to clarify these indications. the aim of this study is to prospectively establish the values of the isis score to obtain an acceptable recurrence rate of long-term instability


Eligibility criteria:
inclusion criteria: * major patient * patient who already volunteered in a first isis study inclusion criteria of the isis study: * patients operated between december 2007 and december 2008 for recurrent shoulder instability, according to the arthroscopic procedure (arthroscopic bankart) in the investigative centers and presenting at the time of the indication of operation an isis score of ≤ 4 points (regardless of the positive criteria) (see annex 2- isis score) * age\> 16 years * supported by a joint arthroscopic technique completed. * patient not objecting to his participation in the study exclusion criteria (same as those of the isis study) * first dislocation or resumption of another technique at the time of indication for surgery * voluntary or multidirectional instability at the time of the indication of operation * painful shoulder without instability felt at the time of the operative indication * lesion of the cap (perioperative report) * humeral lesions avulsion gleno-humeral ligament (per-operative finding) * unsuccessful technique * major benefiting from a legal protection measure (safeguard of justice, trusteeship, guardianship)

Keywords: arthroscopy bankart shoulder isis
evaluation of long-term efficacy of bempedoic acid (etc-1002) in patients with hyperlipidemia at high cardiovascular risk

Conditions: Hypercholesterolemia; Atherosclerotic Cardiovascular Disease

Summary: the purpose of this study is to see if bemedoic acid (etc-1002) is effective versus placebo in patients with high cardiovascular risk and elevated ldl cholesterol not adequately controlled by their current therapy.


Eligibility criteria:
inclusion criteria: * fasting ldl-c ≥100 mg/dl * high cardiovascular risk (diagnosis of hefh and/or ascvd) * be on maximally tolerated lipid-modifying therapy (lmt), including maximally tolerated statin either alone or in combination with other lmts exclusion criteria: * total fasting triglyceride ≥500 mg/dl * renal dysfunction or nephrotic syndrome or history of nephritis * body mass index (bmi) ≥50kg/m2 * significant cardiovascular disease or cardiovascular event in the past 3 months

Keywords: hyperlipidemia cholesterol familial hypercholesterolemia atherosclerotic cardiovascular disease ascvd hefh ldl
tors de-intensification protocol version 2.0: dose and volume reduction in the neck

Conditions: Oropharyngeal Cancer; Squamous Cell Carcinoma; Human Papilloma Virus

Summary: this is a single-arm phase ii study of adjuvant radiation for locally advanced p16+ oropharyngeal squamous cell carcinoma. the main purpose of this research is to determine the likelihood of cancer growing back in the throat or in the neck two years after completion of radiation if lower doses of radiation are used to a smaller area of the head and neck region than is currently used in standard of care.

this is a single arm phase ii study of adjuvant radiation for locally-advanced p16+ oropharyngeal squamous cell carcinoma. patients with pt0-t3, n0-n2b, m0 disease (per ajcc 7th ed) with \<5 positive lymph nodes, will be eligible. patients will have undergone tors primary site resection and ipsilateral neck dissection. patients will undergo radiation dose reduction and target volume reduction.

Eligibility criteria:
inclusion criteria: * patients \>= 18 years old * histologically confirmed diagnosis of squamous cell carcinoma of the oropharynx, p16-positive on immunohistochemistry * pathologic t0 (unknown primary), t1, t2, or t3 disease (per ajcc 7th ed) * pathologic n0, n1, n2a, or n2b disease (per ajcc 7th ed), with \< 5 positive lymph nodes * ecog performance status 0-1 exclusion criteria: * prior radiation therapy to the head and neck * presence of t4 disease * presence of n2c or n3 neck disease (per ajcc 7th ed) * \>= 5 lymph nodes * presence of distant metastatic disease
low-dose digital radiographs in the idiopathic scoliosis

Conditions: Idiopathic Scoliosis

Summary: the aim of the study is to evaluate the intraobserver repeatability and the interobserver reproducibility of low-dose radiographs with a helios drf (cat) imaging system in patients with idiopathic scoliosis.

the 80% of scoliosis is idiopathic and begins mostly in adolescence (10-20 years). the young patients need to undergo several radiographic controls for a correct therapeutic balance. however, the repeated radiation exposures is associated with a greater risk of carcinogenesis even if reduced with a digital imaging technique. the aim of this study is to evaluate the intraobserver repeatability and the interobserver reproducibility of low-dose radiographs with a helios drf (cat) imaging system in patients with idiopathic scoliosis.

Eligibility criteria:
inclusion criteria: * patients with suspected or known idiopathic scoliosis * patients able to maintain orthostasis without medical devices * patients from 9 to 20 years old exclusion criteria: * patients with known congenital, syndromic, neurological scoliosis * patients not able to maintain orthostasis * obese patients * low back pain or known tumor pathology * patients with vertebral arthrodesis * patients younger than 9 years old, or older than 20 years old

Keywords: idiopathic scoliosis radiographs low dose
community pharmacists and opioid misuse

Conditions: Opioid Misuse

Summary: opioid medication misuse and overdose have reached epidemic proportions in the us. community pharmacy is a potentially valuable resource for addressing opioid medication misuse. this study will manualize and establish the feasibility, acceptability, and clinical effect of a community pharmacist-led intervention aimed at: improving opioid mediation regimen adherence, eliminating misuse, connecting patients to additional care, and safeguarding against overdose.

the current small scale single-blinded randomized controlled study will build on our preliminary studies by manualizing and examining the feasibility, acceptability, and clinical effect for the brief intervention medication therapy management (bi-mtm) model. bi-mtm is a multicomponent community pharmacy-based intervention. bi-mtm is designed to: (1) promote opioid medication regimen adherence, (2) reduce opioid medication misuse, (3) connect participants with patient navigation (a chronic condition care model) to increase self-management of health conditions that increase risk for misuse, and (4) provide naloxone rescue training referrals. patients will be screened across 14 months for opioid medication misuse in an urban community pharmacy affiliated with a major medical system. patients positive for misuse will be randomly assigned to bi-mtm (n=23) or standard medication counseling (n=23). standard medication counseling is the centers for medicaid and medicare services requirement for pharmacists in the us wherein pharmacy patients filling prescriptions receive information and opt-in counseling. this study will demonstrate feasibility and acceptability of bi-mtm for community pharmacy patients who misuse their opioid medications for future intervention implementation in a fully powered randomized trial. this study will also generate preliminary data regarding opioid medication misuse elimination and increases in participant self-management activation for comorbid health conditions that increase risk for misuse.

Eligibility criteria:
inclusion criteria: * opioid misuse -≥18 years * english speaking exclusion criteria: * are pregnant (given potential pre/post-natal opioid use complications among pregnant women/offspring) * cannot provide collateral contact information for ≥2 contact persons (to ensure consistent contact/follow up) * do not have a reliable landline or mobile phone to be contacted by study staff * are only filling buprenorphine (given some formulations are not indicated for pain) * plan to leave the area for an extended period of time in the next 3 months * have had a psychotic and/or manic episode in the last 30 days

Keywords: pharmacy intervention medication adherence
ultrasound shear wave elastography in parkinson's disease

Conditions: Parkinson Disease

Summary: parkinson's disease (pd) is a progressive neurodegenerative disorder characterized by motor symptoms including muscle rigidity as one of major motor symptoms affecting quality of life of parkinson's disease patients, thus we aim to assess and quantify muscle stiffness in those patients using ultrasound shear wave elastography .

parkinson's disease (pd) is a progressive neurodegenerative disorder characterized by motor symptoms like tremors, bradykinesia, muscle rigidity, and postural instability, as well as various non-motor symptoms . while the exact cause of parkinson's disease is not fully understood, it is thought to result from a combination of genetic and environmental factors, leading to the degeneration of dopamine-producing neurons in the brain . pd is the second most common neurodegenerative disorder after alzheimer's disease, primarily affecting those over 60, with a higher prevalence in men . the disease significantly impacts quality of life due to progressive motor and non-motor disabilities, and while treatments can alleviate symptoms, there is currently no cure . disease progression and prognosis vary, with advanced stages often leading to severe disability and reduced life expectancy . muscle rigidity, one of the major motor symptoms, refers to the increased resistance when muscles are passively stretched . accurate assessment of muscle stiffness is essential for monitoring disease progression and evaluating therapeutic interventions . traditionally, clinical assessment tools like the unified parkinson's disease rating scale (updrs), part iii, are used to evaluate rigidity severity in pd patients . these assessments, involving manual joint movement and muscle palpation by professionals, are subjective and prone to error . thus, there is a growing need for noninvasive, quantitative tools to assess muscle stiffness in pd patients . tools like electromyography (emg) and myotonometry offer quantitative measurements . ultrasound shear wave elastography (swe) is another non-invasive technique that measures tissue stiffness by analyzing shear wave propagation. while swe shows promise for various conditions, its application in pd-related muscle rigidity remains relatively unexplored .

Eligibility criteria:
inclusion criteria: * patient diagnosed with parkinson's disease * age between 40-85 years * no other neurological or musculoskeletal disorders affecting the examined limb muscles. exclusion criteria: * history of other neurological or musculoskeletal disorders affecting the examined limb muscles. * history of significant trauma or surgery in the examined limb within the last year. * patients with contraindications to ultrasound( such as open skin wounds or severe skin conditions in the area of interest).

Keywords: ultrasound swe parkinson disease
a study to evaluate addition of peginterferon alfa-2a to chronic hepatitis b (chb) patients treated with nas

Conditions: Chronic Hepatitis B

Summary: this study evaluates whether addition of peginterferon alfa-2a to chb patients treated with nucleoside analogues (nas) can enhance the rate of hbsag clearance at end of treatment. this study is a randomized, open-label, multi-center study. the chb patients with nas treatment and have achieved hbv dna \<15 iu/ml、hbeag \<100 peiu/ml、hbsag positive and hbsag\<1500 iu/ml will be randomized into 2 groups: group 1 (combination group): maintain nas treatment while add 48-week standard treatment by peginterferon alfa 2a 180µg/week group 2 (mono na group) : maintain nas treatment for 49 weeks. note: nas including: lam, adv, etv, or tdf.


Eligibility criteria:
inclusion criteria: * male and female patients \>18 and ≤65 years of age; * diagnosed chronic hepatitis b (hbsag(+) for over 6 months before nucleos(t)ide analogues treatment) * patients had achieved hbv dna\<15 iu/ml、hbeag\<100 peiu/ml、hbsag positive and hbsag\<1500 iu/ml on treatment of nucleoside (acid) analogues (including lam, adv, etv, and tdf ) exclusion criteria: * decompensated liver disease: including ascites, hepatic encephalopathy, esophagogastric-varicosis and fissure bleeding and other decompensated complication; * hypersensitive to interferon(ifn) or its active substance, and ineligible to ifn; * a history of immunoregulation drug therapy within 1 year before entry including ifn and so on; * coinfection with hav、hcv、hdv、hev 、hiv or with other chronic liver diseases such as alcoholic liver disease,inherited metabolic liver disease,drug induced liver disease and nonalcoholic fatty liver, autoimmune disease including autoimmune hepatitis and psoriasis and so on; * hepatocellular carcinoma(hcc) or alpha feto protein(afp) levels more than 100ng/ml and hepatic malignant potential of imaging examination or afp levels more than 100 ng/ml for 3 months; * a neutrophil count of less than 1500 per cubic millimeter or a platelet count of less than 90,000 per cubic millimeter; * a serum creatinine level that was more than 1.5 times the upper limit of the normal range; * with other malignant tumors(exclude the cured ones); * severe organ dysfunction; * with severe psychiatric condition or nervous disease such as epilepsy, depression, mania, epilepsy, schizophrenia and so on; * uncontrolled diabetes, hypertension or thyroid disease; * pregnant women and lactating women or patients with pregnancy plans and not willing to use contraception during the study period; * participate in other clinical studies at the same time; * patients unsuitable for the research;